



Supplementary Figure S1: Progression-free survival analysis in BL cohort dichotomized by (A) Surgery, (B) CA19-9 levels before surgery with a cut-off of 100 U/ml and (C) type of chemotherapy received being A+G nab-paclitaxel and gemcitabine and F, FOLFIRINOX regimens. Breslow or Log-rank test were used to test for statistical significance. **, * in the figures indicate very significant ($p < 0.01$) and highly significant ($p < 0.001$) statistical differences respectively. Ns, no significant differences ($p > 0.05$).**